On December 2, 2015, Santhera Pharmaceuticals Holding AG (SIX: SANN) (Santhera) successfully completed a private placement of 590,000 new shares via an accelerated book building process and raised gross proceeds of CHF 54.8 million. The shares, which represent a 10.4% increase in Santhera's issued share capital, were sold at a price of CHF 93.00 per share. Santhera is a Swiss specialty pharmaceutical company focused on the development and commercialization of products for the treatment of orphan mitochondrial and neuromuscular diseases.

Santhera was advised by Homburger in this transaction. The Homburger team was led by partner Dieter Gericke (Corporate | M&A) and included associates Daniel Häusermann and Marc Hanslin (both Corporate | M&A).